<DOC>
	<DOCNO>NCT01405950</DOCNO>
	<brief_summary>A Single-Dose , Phase 1b , Multicenter , Open-Label Study Assess Pharmacokinetics , Safety Tolerability , Pharmacodynamics Tizanidine 4 Different Oral Dose Levels Pediatric Subjects 2 16 Years Old With Mild Moderate Spasticity Due Cerebral Palsy .</brief_summary>
	<brief_title>Phase 1b Study Tizanidine Pediatric Patients With Cerebral Palsy</brief_title>
	<detailed_description>Evaluation study 's progress amendment remain challenge continue pre-screen failure note area Botox injection inclusion ; family participation refusal / disinterest gastric jejunostomy tube placement . A third protocol amendment improve enrollment discuss Investigators believe amendment would overcome barrier express parent would subject child intense study time commitment without direct benefit . The investigative site notify study close enrollment March 27 , 2012 .</detailed_description>
	<mesh_term>Paralysis</mesh_term>
	<mesh_term>Cerebral Palsy</mesh_term>
	<mesh_term>Muscle Spasticity</mesh_term>
	<mesh_term>Tizanidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>Have clinically diagnose spasticity result cerebral palsy Have motor disability result static , nonprogressive brain injury malformation occur prenatally age 2 year Have mild moderate spasticity screening Have parent legally accept representative able understand comply study requirement voluntarily provide informed consent agree primarily responsible adhere requirement study Have history hypersensitivity allergic reaction tizanidine capsule component Have dietary restriction food allergy conflict standardize meal Have clinically significant psychiatric , gastrointestinal , pulmonary , hematologic , endocrine , cardiovascular , renal , hepatic disease require pharmacologic intervention Have ongoing seizure disorder require medical therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>